| 000 | 01406 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250514162111.0 | ||
| 264 | 0 | _c20031204 | |
| 008 | 200312s 0 0 eng d | ||
| 022 | _a1083-4087 | ||
| 024 | 7 |
_a10.18553/jmcp.2003.9.s2.10 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMucenski, John W | |
| 245 | 0 | 0 |
_aMaximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor. _h[electronic resource] |
| 260 |
_bJournal of managed care pharmacy : JMCP _c |
||
| 300 |
_a10-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aEndpoint Determination |
| 650 | 0 | 4 |
_aFever _xchemically induced |
| 650 | 0 | 4 | _aFilgrastim |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 | _aPolyethylene Glycols |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aShogan, Jeffrey E | |
| 773 | 0 |
_tJournal of managed care pharmacy : JMCP _gvol. 9 _gno. 2 Suppl _gp. 10-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18553/jmcp.2003.9.s2.10 _zAvailable from publisher's website |
| 999 |
_c14350579 _d14350579 |
||